Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients – a randomized trial

References

• Lahtinen P, Kokki H, Hynynen M. Pain after cardiac surgery: a prospective cohort study of 1-year incidence and intensity. Anesthesiology. 2006;105:794–800.
   PubMed Web of Science ®Google Scholar
• Liu SS, Wu CL. Effect of postoperative analgesia on major postoperative complications: a systematic update of the evidence. Anesth Analg. 2007;104:689–702.
   PubMed Web of Science ®Google Scholar
• Fletcher D, Stamer UM, Pogatzki-Zahn E, et al. Chronic postsurgical pain in Europe: An observational study. Eur J Anaesthesiol. 2015;32:725–734.
   PubMed Web of Science ®Google Scholar
• Lahtinen P, Kokki H, Hendolin H, et al. Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery. Anesth Analg. 2002;95:813–819.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Jooste EH, Shi Y, et al. Association between early postoperative acetaminophen exposure and acute kidney injury in pediatric patients undergoing cardiac surgery. JAMA Pediatr. 2018;172:655–663.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091.
   PubMed Web of Science ®Google Scholar
• Valtola A, Kokki H, Gergov M, et al. Does coronary artery bypass surgery affect metoprolol bioavailability. Eur J Clin Pharmacol. 2007;63:471–478.
   PubMed Web of Science ®Google Scholar
• Kokki H, Maaroos M, Ellam S, et al. How do different extracorporeal circulation systems affect metoprolol bioavailability in coronary artery bypass surgery patients. Eur J Clin Pharmacol. 2018;74:785–792.
   PubMed Web of Science ®Google Scholar
• Porela-Tiihonen S, Kokki M, Kokki H. Sufentanil sublingual formulation for the treatment of acute, moderate to severe postoperative pain in adult patients . Expert Rev Neurother. 2017;17:101–111.
   PubMed Web of Science ®Google Scholar
• Kinnunen M, Piirainen P, Kokki H, et al. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58:705–725.
   PubMed Web of Science ®Google Scholar
• Ruetzler K, Blome CJ, Nabecker S, et al. A randomised trial of oral versus intravenous opioids for treatment of pain after cardiac surgery. J Anesth. 2014;28:580–586.
   PubMed Web of Science ®Google Scholar
• Smith K, Hopp M, Mundin G, et al. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther. 2008;30:2051–2068.
   PubMed Web of Science ®Google Scholar
• Mundin GE, Smith KJ, Mysicka J, et al. Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times. Expert Opin Drug Metab Toxicol. 2012;8:1495–1503.
   PubMed Web of Science ®Google Scholar
• Berger MM, Berger-Gryllaki M, Wiesel PH, et al. Intestinal absorption in patients after cardiac surgery. Crit Care Med. 2000;28:2217–2223.
   PubMed Web of Science ®Google Scholar
• Parolari A, Alamanni F, Cannata A, et al. Off-pump versus on-pump coronary artery bypass: meta-analysis of currently available randomized trials. Ann Thorac Surg. 2003;76:37–40.
   PubMed Web of Science ®Google Scholar
• Kokki M, Heikkinen M, Välitalo P, et al. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine. Br J Clin Pharmacol. 2017;83:791–800.
   PubMed Web of Science ®Google Scholar
• Piirainen P, Kokki H, Anderson BJ, et al. Analgesic efficacy and pharmacokinetics of epidural oxycodone in pain management after gynaecological laparoscopy – a randomised, double blind, active control, double-dummy clinical comparison with intravenous administration . Br J Clin Pharmacol. 2019;85:1798–1807.
   PubMed Web of Science ®Google Scholar
• Kokki M, Välitalo P, Rasanen I, et al. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Eur J Clin Pharmacol. 2012;68:1357–1363.
   PubMed Web of Science ®Google Scholar
• Lamminsalo M, Piirainen P, Kokki H, et al. Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. Expert Opin Drug Deliv. 2019;16:649–656.
   PubMed Web of Science ®Google Scholar
• Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–151.
   PubMed Web of Science ®Google Scholar
• FIMEA. Databeases and Registers: [Inretnet]. Kuopio (FI): Finnish Medicine Agency, FIMEA. SPC. TARGINIQ. [Cited 2019 Dec 19]. Available from: http://spc.fimea.fi/indox/nam/html/nam/humspc/4/10878364.pdf
   Google Scholar
• Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20:427–439.
   PubMed Web of Science ®Google Scholar
• Hall R. The pharmacokinetic behaviour of opioids administered during cardiac surgery. Can J Anaesth. 1991;38:747–756.
   PubMed Web of Science ®Google Scholar
• Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000; 44:261–273.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996;42:747–756.
   PubMed Web of Science ®Google Scholar
• Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24:344–354.
   PubMed Web of Science ®Google Scholar
• Ishida T, Oguri K, Yoshimura H. Determination of oxycodone metabolites in urines and feces of several mammalian species. J Pharmacobio-Dyn. 1982;5:521–525.
   PubMedGoogle Scholar
• Reder RF, Oshlack B, Miotto JB, et al. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996;18:95–105.
   PubMed Web of Science ®Google Scholar
• Lahtinen P, Kokki H, Hakala T, et al. S(+)-ketamine as analgesic adjunct reduces opioid consumption after cardiac surgery. Anest Analg. 2004;99:1295–1301.
   PubMed Web of Science ®Google Scholar
• Lahtinen P, Kokki H, Hynynen M. Remifentanil infusion does not induce opioid tolerance after cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22:225–229.
   PubMed Web of Science ®Google Scholar
• Välitalo P, Ranta VP, Hooker AC, et al. Population pharmacometrics in support of analgesics studies. Acta Anaesthesiol Scand. 2014;58:143–156.
   PubMed Web of Science ®Google Scholar
• Kokki M, Kuronen M, Naaranlahti T, et al. Opioid-induced bowel dysfunction in patients undergoing spine surgery: comparison of oxycodone and oxycodone-naloxone treatment. Adv Ther. 2017;34:236–251.
   PubMed Web of Science ®Google Scholar